BioCryst presents first interim real-word evidence from APeX-N trial

BioCryst announced the presentation of six posters, including the first interim real-word evidence from the APeX-N trial, and new data highlighting the value of shared decision making, or SDM, between healthcare providers, or HCPs, and their hereditary angioedema, or HAE, patients to provide optimal patient outcomes. APeX-N is a European multi-center observational study assessing the safety, effectiveness and quality of life of berotralstat 150 mg in routine clinical use. This interim analysis included 56 patients from the United Kingdom, France, Germany and Sweden. Non-serious gastrointestinal adverse events were reported in 12.5 percent of patients. Seven percent of patients discontinued treatment. One patient had a severe HAE attack but continued treatment. This study, conducted in Germany, explored the dynamics between HCPs and patients in HAE management, identifying barriers to SDM and strategies to improve it. Ten HCPs participated in 60-minute interviews and simulated patient consultations. Eight HAE patients participated in 30-minute interviews. Participants then convened in structured focus groups to discuss their findings. The participants identified a need for enhanced HCP awareness of patient perspectives, more comprehensive HCP-patient conversations and improved education about HAE treatment management.